Preliminary development and internal evaluation of a plasma SOX1 methylation-based model bladder cancer detection
- 1Department of Urology , The Second People’s Hospital of Shizuishan , , 753000 , ,
Abstract
The evaluation of individuals with suspected bladder cancer (BCa) continues to rely on cystoscopy, while urine cytology demonstrates limited sensitivity. This single-center retrospective two-gate case-control study included 90 individuals (30 with BCa and 60 non-cancer controls). SOX1 methylation signals in plasma-derived DNA were quantified using quantitative methylation-specific PCR. Logistic regression was used to generate a SOX1-only model and a combined model incorporating SOX1 methylation, age, and sex. Model performance was described using apparent ROC-AUC, sensitivity, specificity and other operating characteristics at the Youden-derived cut-off, together with internal bootstrap, five-fold cross-validation, calibration, and exploratory decision-curve analysis (DCA). All resampling procedures used the same 90 participants; no independent validation cohort was available. PAX1 methylation was assessed as a prespecified exploratory single-marker comparator. In this selected sample, the combined model had a higher apparent AUC than the SOX1-only model (0.882 vs 0.828). At the Youden-derived threshold, sensitivity was 83.3 % and specificity was 88.3 %. Exploratory DCA favored the combined model within the study sample, but this estimate is dependent on the fixed case-control sampling fraction. The PAX1-only AUC methylation was 0.845, numerically higher than the SOX1-only AUC, although PAX1 was not included in multivariable modeling. Adding age and sex to the plasma SOX1 methylation signal improved apparent discrimination within this small selected cohort. This preliminary, hypothesis-generating model is not validated for clinical use and should not be assumed to generalize to consecutive hematuria populations. Independent prospective evaluation in larger, clinically representative cohorts is required.
Related
- Development and initial evaluation of a urine DNA methylation assay for pan-urinary cancer detection
- Epigenome-Wide DNA Methylation Profiling of Matched Primary Breast Cancers and Brain Metastases Reveals Epigenetic Markers linked to Metastatic Progression: A Preliminary Study.
- Development and evaluation of a multiplex PCR for simultaneous detection of Mycobacterium tuberculosis complex, Mycobacterium avium complex, and Burkholderia pseudomallei in clinical specimens
- Mutation of Drosophila Lsd1 Disrupts H3-K4 Methylation, Resulting in Tissue-Specific Defects during Development
- A Batch-Aware, Subject-Grouped Pipeline to Prioritize HIIT-Associated DNA Methylation Candidates with Cross-Cohort Evaluation in Skeletal Muscle
BibTeX
@article{zhang2026preliminary,
title = {{Preliminary development and internal evaluation of a plasma SOX1 methylation-based model bladder cancer detection}},
author = {Guangtao Zhang and Jiangning Mu and Xuezhen Shi and Zhenhu Bao and Yonghong Ma and Li Kong and Lin Zhao and Dingming Bai and Yuyong Ding and Peng Du and Fei Dong},
journal = {Open life sciences},
year = {2026},
month = nov,
doi = {10.1515/biol-2025-1396},
url = {https://europepmc.org/article/PMC/PMC13730398},
note = {CC BY},
}
RIS
TY - JOUR
TI - Preliminary development and internal evaluation of a plasma SOX1 methylation-based model bladder cancer detection
AU - Guangtao Zhang
AU - Jiangning Mu
AU - Xuezhen Shi
AU - Zhenhu Bao
AU - Yonghong Ma
AU - Li Kong
AU - Lin Zhao
AU - Dingming Bai
AU - Yuyong Ding
AU - Peng Du
AU - Fei Dong
PY - 2026
DA - 2026/11/04
JO - Open life sciences
DO - 10.1515/biol-2025-1396
UR - https://europepmc.org/article/PMC/PMC13730398
AB - The evaluation of individuals with suspected bladder cancer (BCa) continues to rely on cystoscopy, while urine cytology demonstrates limited sensitivity. This single-center retrospective two-gate case-control study included 90 individuals (30 with BCa and 60 non-cancer controls). SOX1 methylation signals in plasma-derived DNA were quantified using quantitative methylation-specific PCR. Logistic regression was used to generate a SOX1-only model and a combined model incorporating SOX1 methylation, age, and sex. Model performance was described using apparent ROC-AUC, sensitivity, specificity and other operating characteristics at the Youden-derived cut-off, together with internal bootstrap, five-fold cross-validation, calibration, and exploratory decision-curve analysis (DCA). All resampling procedures used the same 90 participants; no independent validation cohort was available. PAX1 methylation was assessed as a prespecified exploratory single-marker comparator. In this selected sample, the combined model had a higher apparent AUC than the SOX1-only model (0.882 vs 0.828). At the Youden-derived threshold, sensitivity was 83.3 % and specificity was 88.3 %. Exploratory DCA favored the combined model within the study sample, but this estimate is dependent on the fixed case-control sampling fraction. The PAX1-only AUC methylation was 0.845, numerically higher than the SOX1-only AUC, although PAX1 was not included in multivariable modeling. Adding age and sex to the plasma SOX1 methylation signal improved apparent discrimination within this small selected cohort. This preliminary, hypothesis-generating model is not validated for clinical use and should not be assumed to generalize to consecutive hematuria populations. Independent prospective evaluation in larger, clinically representative cohorts is required.
SN - 2391-5412
ER -